0.000USD0.000Pre-market 07/24, 09:30 (ET)
1.41BMarket Cap
LossP/E TTM
Key Figures
28.200Open
28.610High
3.00Volume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.00%Turnover Ratio
27.690Prev. Close
27.500Low
57.00Turnover
413.67P/E Static
3.97P/B
0.00%Div Yield TTM
-32.57%ROA
53.65052wk High
-0.00Volume Ratio
3.40MNet Profit
49.34MShares
-2.3549EPS TTM
--Beta
-38.67%ROE
9.73252wk Low
4.01%Amplitude
100.00%Gross Margin
1.41BMarket Cap
1.03Reward/Risk
3.70%Risk Rate
Currency: USD Updated: 2026-07-23 Key Insights
Maze Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 5 out of 386 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 63.50.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Maze Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Maze Therapeutics Inc Highlights
StrengthsRisks
Maze Therapeutics Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Maze Therapeutics Inc
MAZE
12
Ionis Pharmaceuticals Inc
IONS
26
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Maze Therapeutics Inc Info
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
Ticker SymbolMAZE
CompanyMaze Therapeutics Inc
CEOColoma (Jason V)
Websitehttps://www.mazetx.com/
Shareholders
FAQs
What is the current price of Maze Therapeutics Inc (MAZE)?
The current price of Maze Therapeutics Inc (MAZE) is 27.66.
What is the symbol of Maze Therapeutics Inc?
The ticker symbol of Maze Therapeutics Inc is MAZE.
What is the 52-week high of Maze Therapeutics Inc?
The 52-week high of Maze Therapeutics Inc is 53.65.
What is the 52-week low of Maze Therapeutics Inc?
The 52-week low of Maze Therapeutics Inc is 9.73.
What is the market capitalization of Maze Therapeutics Inc?
The market capitalization of Maze Therapeutics Inc is 1.36B.
Is Maze Therapeutics Inc (MAZE) currently rated as Buy, Hold, or Sell?
According to analysts, Maze Therapeutics Inc (MAZE) has an overall rating of Buy, with a price target of 63.50.
What is the Earnings Per Share (EPS TTM) of Maze Therapeutics Inc (MAZE)?
The Earnings Per Share (EPS TTM) of Maze Therapeutics Inc (MAZE) is -3.05.
